'For the quarter ending Dec 2023, consolidated Net sales (including other operating income) of Dr Reddys Laboratories has increased 6.58% to Rs 7236.8 crore compared to quarter ended Dec 2022.  Sales of Pharmaceutical Services segment has gone up 2.68% to Rs 1,058.00 crore (accounting for 14.12% of total sales).  Sales of Global Generics segment has gone up 6.49% to Rs 6,312.40 crore (accounting for 84.26% of total sales).  Sales of Others segment has gone up 73.08% to Rs 121.50 crore (accounting for 1.62% of total sales).  Inter-segment sales rose Rs 238.40 crore to Rs 255.10 crore.  

Profit before interest, tax and other unallocable items (PBIT) has jumped 5.26% to Rs 4,220.70 crore.  PBIT of Pharmaceutical Services segment rose 63.27% to Rs 230.70 crore (accounting for 5.47% of total PBIT).  PBIT of Global Generics segment rose 2.15% to Rs 3,907.70 crore (accounting for 92.58% of total PBIT). &...

• 

  (13-Jan-2025)

  Avenue Supermarts

  Revenue up 17.7% YoY, Net profit up 4.8% YoY in Q3FY2025

• 

  (12-Jan-2025)

  Just Dial

  Sales up 8%, net up 43%

• 

  (10-Jan-2025)

  PCBL

  Lower profits

• 

  (10-Jan-2025)

  Tata Consultancy Services

  Revenue up 5.6% YoY to Rs 63973 crore in Q3FY2025